C.R. Bard (BCR) 221.21 $BCR CR Bard (BCR) Breaks Through

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
C.R. Bard (BCR) 221.21 $BCR

CR Bard (BCR) Breaks Through Resistance at $221.54
Comtex SmarTrend(R) - Wed Aug 31, 8:51AM CDT
Shares of CR Bard (NYSE:BCR) have bullishly opened above the pivot of $220.86 today and have reached the first resistance level of $221.54. Investors may be interested in a cross of the next upside pivot targets of $221.97 and $223.08.
BCR: 221.21 (-0.29)

Watch for CR Bard to Potentially Pullback After Gaining 1.56% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 1:27PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 221.21 (-0.29)

SmarTrend Watching for Potential Pullback in Shares of CR Bard After 1.56% Gain
Comtex SmarTrend(R) - Mon Aug 29, 1:25PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $217.06 to a high of $220.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $218.13 on volume of 234,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 221.21 (-0.29)

After Yesterday's Decline of 1.10%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 16, 2:51PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

Look for Shares of CR Bard to Potentially Rebound after Yesterday's 1.10% Sell Off
Comtex SmarTrend(R) - Tue Aug 16, 2:49PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.55 to a high of $221.56. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $220.86 on volume of 215,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

CR Bard Falls 1.44% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Aug 03, 2:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

SmarTrend Watching for Potential Rebound in Shares of CR Bard After 1.44% Loss
Comtex SmarTrend(R) - Wed Aug 03, 2:11PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $219.32 to a high of $222.63. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $220.45 on volume of 244,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

Cardinal Health (CAH) Tops Q4 Earnings, '17 View Impressive
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:59PM CDT
Cardinal Health Inc. (CAH) reported fourth-quarter fiscal 2016 adjusted earnings of $1.14 per share, which beat the Zacks Consensus Estimate by a penny.
BCR: 221.21 (-0.29), ALGN: 95.78 (+2.02), CAH: 79.73 (+0.03), MMSI: 24.49 (+0.09)

CONMED (CNMD) Earnings & Sales Beat in Q2, '16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:45AM CDT
CONMED Corporation (CNMD) reported second-quarter 2016 adjusted earnings of 47 cents per share, surpassing the Zacks Consensus Estimate.
ABC: 87.44 (+0.29), BCR: 221.21 (-0.29), ALGN: 95.78 (+2.02), CNMD: 40.99 (+0.43)

C.R. Bard (BCR) Beats Q2 Earnings & Sales, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:19PM CDT
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.56 in the second quarter of 2016, exceeding the Zacks Consensus Estimate by a dime.
HYH: 36.57 (+0.32), BSX: 24.26 (-0.07), BCR: 221.21 (-0.29), ALGN: 95.78 (+2.02)

SmarTrend Watching for Potential Rebound in Shares of CR Bard After 4.07% Loss
Comtex SmarTrend(R) - Wed Jul 27, 2:05PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

After Yesterday's Decline of 4.07%, CR Bard Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 27, 2:03PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $221.01 to a high of $229.92. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $228.34 on volume of 467,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BCR: 221.21 (-0.29)

LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 12:16PM CDT
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
SQNM: 2.40 (unch), BCR: 221.21 (-0.29), LH: 137.71 (+1.58), COO: 185.92 (+0.55)

LabCorp Sees Balanced Growth; Covance Synergy on Track
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 6:00AM CDT
On Jun 20, 2016, we issued an updated research report on Laboratory Corporation of America Holdings (LH).
BCR: 221.21 (-0.29), LH: 137.71 (+1.58), HSIC: 164.29 (+1.31), COO: 185.92 (+0.55)

23.8% Return Seen to Date on SmarTrend CR Bard Call (BCR)
Comtex SmarTrend(R) - Mon Jun 20, 1:40PM CDT
SmarTrend identified an Uptrend for CR Bard (NYSE:BCR) on January 25th, 2016 at $184.50. In approximately 5 months, CR Bard has returned 23.85% as of today's recent price of $228.50.
BCR: 221.21 (-0.29)

DENTSPLY Sirona (XRAY): Q1 Strong, Expansion on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
On Jun 17, we issued an updated research report on NY-based DENTSPLY Sirona Inc. (XRAY).
HYH: 36.57 (+0.32), BCR: 221.21 (-0.29), CNMD: 40.99 (+0.43), XRAY: 61.70 (+0.05)

Becton, Dickinson (BDX) Inks Partnership Deal with CAPS
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 6:07AM CDT
Becton, Dickinson and Company (BDX) recently announced a partnership with Central Admixture Pharmacy Services (CAPS).
HYH: 36.57 (+0.32), BDX: 177.32 (+0.30), BCR: 221.21 (-0.29), MDT: 87.32 (+0.34)

CR Bard Up 21.7% Since SmarTrend Uptrend Call (BCR)
Comtex SmarTrend(R) - Fri Jun 10, 1:50PM CDT
SmarTrend identified an Uptrend for CR Bard (NYSE:BCR) on January 25th, 2016 at $184.50. In approximately 5 months, CR Bard has returned 21.65% as of today's recent price of $224.45.
BCR: 221.21 (-0.29)

Bard Announces $500 Million Share Repurchase Authorization
BusinessWire - Wed Jun 08, 3:15PM CDT
The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today authorized the repurchase of up to $500 million of the company's common stock. This is in addition to approximately $205 million remaining under the prior authorization announced in June 2015. Share repurchases will be made from time-to-time in the open market or through privately negotiated transactions.
BCR: 221.21 (-0.29)

Bard Increases Quarterly Dividend
BusinessWire - Wed Jun 08, 3:15PM CDT
The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today increased the quarterly dividend on Bard's common stock by 8 percent, to 26 cents per share. The dividend is payable on July 29, 2016 to shareholders of record at the close of business on July 18, 2016. This will be the 45th consecutive calendar year in which Bard has increased its annual dividend payout to shareholders.
BCR: 221.21 (-0.29)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 39

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 287

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 116

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 187

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

IONQ Achieves Record Stock Levels Amid Strong Growth Indicators

Updated Category News Views 243

IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....

Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth

Updated Category News Views 285

Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...

Continue Reading
Texas Instruments: Unusual Options Trends Uncovered

Updated Category News Views 195

Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...

Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025

Updated Category News Views 177

SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...

Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump

Updated Category News Views 159

Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...

Continue Reading